|
5iTech, LLC |
|
International Technology Capitalization & Commercialization |
|
Home |
|
5iTech’s objective is to advance to market superior technology products and participate in the resulting commercial success. A vehicle for technology commercialization, 5iTech works with inventors, entrepreneurs and industry partners to achieve this objective. 5iTech leverages the experience and expertise of its team to launch technology based startups and assist established companies acquire and develop new products. A leader in cross-border technology transfer and commercialization, 5iTech achieves a competitive edge by relying on its extensive pipeline of innovations developed by former Soviet scientists. Our approach is distinguished by its emphasis on building true partnerships with innovators, corporations and capital sources. |
|
5iTech, LLC 1768 East 25th Street Cleveland, OH 44114 United States of America |
|
To contact us: |
|
Leon Polott, CEO Phone: 216-391-7765 Fax: (216) 274-9285 E-mail: lapolott@5itech.com |
|
|
|
Home |
|
Approach |
|
Services |
|
5iTech Team |
|
Portfolio Companies |
|
Affiliates |
|
Contact |
|
Sterionics, Inc., a 5iTech startup, demonstrates that its technology can eliminate staph infection in 3 second at preliminary validation trials at the Calhoun Lab of the Akron General Medical Center.
|
|
Oculatek, a 5iTech company, commences clinical trials in US. |
|
Robert C. Cresanti, the former Under Secretary of the United States Department of Commerce for Technology, agrees to join the Board of Directors of 5iTech’s venture management affiliate, CTD International—the general partner in The Parus Fund I. |
|
CTD International, LLC the 5iTech venture management affiliate, receives initial $10 Million anchoring commitment for its early stage venture fund—The Parus Fund I. |
